Li, W., Zou, J., Chang, J., Wang, C., Huang, M., Chen, Z., Zhu, X., Guo, W. (2026). Second-line irinotecan followed by third-line cetuximab plus irinotecan versus second-line cetuximab combined with irinotecan in treatment of oxaliplatin/5-FU failure RAS/RAF wild-type mCRC patients: A randomized phase II study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.2_suppl.148